Article Text
Letter
Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis
Statistics from Altmetric.com
Etanercept and infliximab are soluble tumour necrosis factor α (TNFα) antibodies. Etanercept is approved for the treatment of polyarticular juvenile rheumatoid arthritis (JRA), and infliximab is in the process of being approved. We report the first case in which the same patient developed a non-obstructive, sterile cholecystitis with etanercept (Enbrel) and later with infliximab (Remicade).
CASE REPORT
A 15 year old white female patient with polyarticular JRA, treated with a combination of 14 mg/m2 methotrexate once a week intramuscularly and 2 g sulfasalazine a day, did not show any …